Guidance, NICE advice and quality standards in development | Guidance

Showing 281 to 290 of 318

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]	Technology appraisal guidance	TBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]	Technology appraisal guidance	26 November 2025
Teprotumumab for treating thyroid eye disease [ID6432]	Technology appraisal guidance	TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379	Technology appraisal guidance	TBC
Third molars (impacted) - prophylactic removal [ID898]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]	Technology appraisal guidance	TBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113	Technology appraisal guidance	TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]	Technology appraisal guidance	TBC